Processa Pharmaceuticals, Inc.(PCSA)Earnings, Financials & Key Ratios
PCSA•NASDAQ
$2.75
$7M mkt cap·Price updated May 6, 2026
AboutProcessa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.Show more
- Revenue$0
- EBITDA-$14M-16.1%
- Net Income-$14M-14.5%
- EPS (Diluted)-10.36+89.3%
- ROE-372.97%-5.2%
- ROIC-3391.36%-89.8%
PCSA Key Insights
Processa Pharmaceuticals, Inc. (PCSA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 98 (top 2%)
- ✓Trading at only 0.6x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PCSA Price & Volume
Processa Pharmaceuticals, Inc. (PCSA) stock price & volume — 10-year historical chart
Loading chart...
PCSA Growth Metrics
Processa Pharmaceuticals, Inc. (PCSA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-14.46%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-7479.96%
Return on Capital
10 Years-286.83%
5 Years-227.52%
3 Years-307.43%
Last Year-384.62%
PCSA Peer Comparison
Processa Pharmaceuticals, Inc. (PCSA) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ATHA | 17.12M | 4.34 | -0.17 | -340.97% | 0.03 | |||
 NUVB | 1.75B | 5.04 | -8.40 | 6.99% | -102.06% | -44.1% | 0.03 | |
 CRVS | 1.15B | 15.45 | -29.15 | -23.29% | 0.02 | |||
 CASI | 2.33M | 0.15 | -0.06 | -15.77% | -183.93% | -301.8% | 11.96 | |
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 MNKD | 1.1B | 3.56 | 178 | 22.23% | -6.63% | |||
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 ALDX | 104.68M | 1.74 | -1.85 | -87.71% | 0.22 |
Compare PCSA vs Peers
Processa Pharmaceuticals, Inc. (PCSA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PCSA Income Statement
Processa Pharmaceuticals, Inc. (PCSA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | -100% | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 882.06K | 0 | 0 | 0 | 0 | 1.2K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | -1.86K▲ 0% | -630.09K▼ 33685.1% | -877.9K▼ 39.3% | -882.06K▼ 0.5% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -1.2K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | -151.53% | -33685.09% | -39.33% | -0.47% | 100% | - | - | - | - |
| Operating Expenses | 1.8M | 4.52M | 3.94M | 14.25M | 12.13M | 27.53M | 11.46M | 12.05M | 13.99M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 876.32K | 1.44M | 1.61M | 3.18M | 4.69M | 8.76M | 5.66M | 4.78M | 6.18M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 926.12K | 3.09M | 2.32M | 11.08M | 6.88M | 11.49M | 5.8M | 7.27M | 7.81M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 566.58K | 7.27M | 0 | 0 | 0 |
| Operating Income | -1.8M▲ 0% | -4.52M▼ 151.0% | -3.94M▲ 13.0% | -15.14M▼ 284.6% | -12.13M▲ 19.8% | -27.53M▼ 126.9% | -11.46M▲ 58.4% | -12.05M▼ 5.2% | -13.99M▼ 16.1% |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 6.2% | -151.05% | 13.03% | -284.63% | 19.84% | -126.85% | 58.38% | -5.19% | -16.08% |
| EBITDA | -1.8M | -3.89M | -3.06M | -14.25M | -11.34M | -26.74M | -11.46M | -12.05M | -13.99M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 6.23% | -116.31% | 21.5% | -366.21% | 20.43% | -135.72% | 57.15% | -5.18% | -16.07% |
| D&A (Non-Cash Add-back) | 1.86K | 630.09K | 877.9K | 882.06K | 790.97K | 788.5K | 222 | 782 | 1.2K |
| EBIT | -1.8M | -4.51M | -3.92M | -15.13M | -11.57M | -20.26M | -11.46M | -12.05M | -13.99M |
| Net Interest Income | -30.51K | -142.91K | -25.11K | -277.95K | 11.63K | 101.2K | 335.54K | 201.09K | 109.49K |
| Interest Income | 5.18K | 18.3K | 11.55K | 3.17K | 11.99K | 101.2K | 335.54K | 201.09K | 109.49K |
| Interest Expense | 35.69K | 161.21K | 36.66K | 281.12K | 362 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -53.88K | -142.91K | -25.11K | -277.95K | 175.4K | 101.2K | 335.54K | 201.09K | 424.67K |
| Pretax Income | -1.86M▲ 0% | -4.67M▼ 151.5% | -3.96M▲ 15.2% | -15.41M▼ 289.2% | -11.96M▲ 22.4% | -27.42M▼ 129.3% | -11.12M▲ 59.4% | -11.85M▼ 6.6% | -13.56M▼ 14.5% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | -18.19K | -902.8K | -602.72K | -1M | -530.61K | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.98% | 19.34% | 15.22% | 6.49% | 4.44% | 0% | 0% | 0% | 0% |
| Net Income | -1.86M▲ 0% | -3.77M▼ 102.8% | -3.36M▲ 10.8% | -19.04M▼ 467.0% | -11.43M▲ 40.0% | -27.42M▼ 140.0% | -11.12M▲ 59.4% | -11.85M▼ 6.6% | -13.56M▼ 14.5% |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -452.5% | -102.82% | 10.81% | -467.02% | 39.98% | -139.98% | 59.45% | -6.55% | -14.46% |
| Net Income (Continuing) | -1.86M | -3.77M | -3.36M | -14.41M | -11.43M | -27.42M | -11.12M | -11.85M | -13.56M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -200.00▲ 0% | -355.00▼ 77.5% | -304.25▲ 14.3% | -1269.25▼ 317.2% | -373.00▲ 70.6% | -42.50▲ 88.6% | -212.00▼ 398.8% | -96.75▲ 54.4% | -10.36▲ 89.3% |
| EPS Growth % | 73.24% | -77.5% | 14.3% | -317.17% | 70.61% | 88.61% | -398.82% | 54.36% | 89.29% |
| EPS (Basic) | -200.00 | -355.00 | -304.25 | -1269.25 | -373.00 | -42.50 | -212.00 | -96.75 | -10.36 |
| Diluted Shares Outstanding | 9.31K | 10.66K | 11.05K | 15K | 30.64K | 32.22K | 52.46K | 122.4K | 1.31M |
| Basic Shares Outstanding | 9.31K | 10.66K | 11.05K | 15K | 30.64K | 32.22K | 52.46K | 122.4K | 1.31M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
PCSA Balance Sheet
Processa Pharmaceuticals, Inc. (PCSA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 2.95M | 2.02M | 1.01M | 16.2M | 18.33M | 8.39M | 5.63M | 1.87M | 5.67M |
| Cash & Short-Term Investments | 2.85M | 1.74M | 691.54K | 15.42M | 16.5M | 6.5M | 4.71M | 1.19M | 5.54M |
| Cash Only | 2.85M | 1.74M | 691.54K | 15.42M | 16.5M | 6.5M | 4.71M | 1.19M | 5.54M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 62.71K | 21.58K | 0 | 231.75K | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 70.27K | 0 | 926.3K | 0 | 133.92K |
| Total Non-Current Assets | 31.36K | 10.46M | 9.88M | 9.01M | 8.14M | 233.12K | 154.15K | 1.36M | 2.14M |
| Property, Plant & Equipment | 25.82K | 17.38K | 228K | 159.04K | 74.18K | 227.59K | 148.61K | 75.69K | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 10.44M | 9.64M | 8.85M | 8.06M | 0 | 0 | 0 | 1.15M |
| Long-Term Investments | 0 | 1.8M | -1.12M | -1.9M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 5.54K | -2.53M | 5.54K | 5.54K | 5.54K | 5.54K | 5.54K | 1.28M | 997.51K |
| Total Assets | 2.98M▲ 0% | 13.21M▲ 343.0% | 10.88M▼ 17.6% | 25.21M▲ 131.7% | 26.46M▲ 5.0% | 8.62M▼ 67.4% | 5.79M▼ 32.9% | 3.23M▼ 44.2% | 7.81M▲ 142.0% |
| Asset Turnover | - | - | - | - | - | - | - | - | - |
| Asset Growth % | 92051.37% | 343.01% | -17.64% | 131.68% | 4.95% | -67.43% | -32.87% | -44.19% | 141.96% |
| Total Current Liabilities | 2.6M | 645.7K | 1.19M | 1.22M | 971.02K | 998.56K | 730.58K | 1.53M | 2.24M |
| Accounts Payable | 50.69K | 292.1K | 75.61K | 320.69K | 218.91K | 327.55K | 311.62K | 880.88K | 1.06M |
| Days Payables Outstanding | - | - | - | 132.7 | - | - | - | - | 320.37K |
| Short-Term Debt | 2.45M | 230K | 802.5K | 117.57K | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 436 | 0 | 316 | 469.86K | 401.77K | 189.05K | 189.04K | 0 | 1.18M |
| Current Ratio | 1.14x | 3.13x | 0.85x | 13.27x | 18.87x | 8.40x | 7.71x | 1.22x | 2.54x |
| Quick Ratio | 1.14x | 3.13x | 0.85x | 13.27x | 18.87x | 8.40x | 7.71x | 1.22x | 2.54x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 9.96K | 2.13M | 1.68M | 1.05M | 7.38K | 150.55K | 66.91K | 487 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 44.88K | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 147.39K | 78.46K | 7.38K | 150.55K | 66.91K | 487 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 1.53M | 530.61K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 9.96K | 2.13M | 0 | 400K | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 2.61M | 3.51M | 2.87M | 2.27M | 978.4K | 1.15M | 797.48K | 1.53M | 2.24M |
| Total Debt | 2.45M | 230K | 1.03M | 328.12K | 78.46K | 229.45K | 150.55K | 73.51K | 0 |
| Net Debt | -398.86K | -1.51M | 336.35K | -15.09M | -16.42M | -6.27M | -4.56M | -1.12M | -5.54M |
| Debt / Equity | 6.56x | 0.02x | 0.13x | 0.01x | 0.00x | 0.03x | 0.03x | 0.04x | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -50.50x | -28.07x | -107.36x | -53.84x | -33518.07x | - | - | - | - |
| Total Equity | 373.16K▲ 0% | 9.7M▲ 2499.7% | 8.01M▼ 17.4% | 22.94M▲ 186.3% | 25.49M▲ 11.1% | 7.47M▼ 70.7% | 4.99M▼ 33.2% | 1.7M▼ 66.0% | 5.58M▲ 228.8% |
| Equity Growth % | 115.87% | 2499.67% | -17.41% | 186.29% | 11.1% | -70.69% | -33.22% | -66% | 228.82% |
| Book Value per Share | 40.07 | 909.70 | 725.05 | 1529.40 | 831.79 | 231.87 | 95.10 | 13.86 | 4.26 |
| Total Shareholders' Equity | 373.16K | 9.7M | 8.01M | 22.94M | 25.49M | 7.47M | 4.99M | 1.7M | 5.58M |
| Common Stock | 3.53K | 3.87K | 549 | 1.42K | 1.57K | 1.61K | 129 | 371 | 257 |
| Retained Earnings | -3.86M | -7.62M | -10.98M | -25.4M | -36.82M | -64.25M | -75.37M | -87.22M | -100.78M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | -300K | -300K | -300K | -300K |
| Accumulated OCI | -3.25K | -1.8M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PCSA Cash Flow Statement
Processa Pharmaceuticals, Inc. (PCSA) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -1.65M | -3.71M | -2.75M | -3.14M | -8.72M | -9.61M | -8.06M | -11.25M | -11.39M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -3729.87% | -124.09% | 25.83% | -14.29% | -177.34% | -10.18% | 16.05% | -39.46% | -1.25% |
| Net Income | -1.86M | -3.77M | -3.36M | -14.41M | -11.43M | -27.42M | -11.12M | -11.85M | -13.56M |
| Depreciation & Amortization | 1.86K | 630.09K | 803.77K | 803.77K | 790.97K | 788.5K | 222 | 782 | 1.2K |
| Stock-Based Compensation | 0 | 74.06K | 510.48K | 2.73M | 3.41M | 8.83M | 1.06M | 629.51K | 857.55K |
| Deferred Taxes | 0 | -902.8K | -602.72K | -1M | -530.61K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 38.7K | 67.07K | 75.91K | 8.88M | 220.61K | 7.66M | 1.39M | 87.18K | -224.5K |
| Working Capital Changes | 161.13K | 188.71K | -179.71K | -140.39K | -1.18M | 543.6K | 605.21K | -112.4K | 1.54M |
| Change in Receivables | 0 | 0 | 0 | -77.02K | 6.75K | 70.27K | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 77.02K | -6.75K | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 241.42K | -216.49K | 245.08K | -101.79K | 108.64K | -15.93K | 569.26K | 175.92K |
| Cash from Investing | 1M | -22.28K | 0 | 0 | 0 | 0 | -2.78K | -3.24K | -850K |
| Capital Expenditures | -20.62K | -22.28K | 0 | 0 | 0 | 0 | -2.78K | -3.24K | -850K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Acquisitions | 6.28K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 1.02M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 2.43M | 2.62M | 1.7M | 17.87M | 9.8M | -388.84K | 6.27M | 7.73M | 16.58M |
| Debt Issued (Net) | 2.58M | 0 | 805K | 862.46K | 0 | 0 | 0 | -5.2K | -6.6K |
| Equity Issued (Net) | 0 | 1000K | 0 | 1000K | 1000K | -300K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | -95.21K | -64.4K | -388.84K | 0 | -15.9K | 0 |
| Other Financing | -154.8K | -250.96K | 895.72K | 0 | -186.49K | -88.84K | -52.75K | -8.56K | -10.4K |
| Net Change in Cash | 1.78M▲ 0% | -1.11M▼ 162.3% | -1.05M▲ 5.2% | 14.72M▲ 1503.1% | 1.08M▼ 92.7% | -9.99M▼ 1024.2% | -1.8M▲ 82.0% | -3.51M▼ 95.6% | 4.35M▲ 223.6% |
| Free Cash Flow | -1.68M▲ 0% | -3.73M▼ 122.6% | -2.75M▲ 26.2% | -3.14M▼ 14.3% | -8.72M▼ 177.3% | -9.61M▼ 10.2% | -8.07M▲ 16.0% | -11.25M▼ 39.5% | -11.39M▼ 1.2% |
| FCF Margin % | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -2401.18% | -122.56% | 26.24% | -14.29% | -177.34% | -10.18% | 16.02% | -39.45% | -1.22% |
| FCF per Share | -179.88 | -349.63 | -248.86 | -209.56 | -284.52 | -298.12 | -153.75 | -91.90 | -8.70 |
| FCF Conversion (FCF/Net Income) | 0.89x | 0.98x | 0.82x | 0.17x | 0.76x | 0.35x | 0.73x | 0.95x | 0.84x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PCSA Key Ratios
Processa Pharmaceuticals, Inc. (PCSA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -497.45% | -74.75% | -37.91% | -123.03% | -47.2% | -166.43% | -178.52% | -354.51% | -372.97% |
| Return on Invested Capital (ROIC) | - | - | -83.13% | -35.69% | -140.15% | -107.58% | -402.32% | -1054.26% | -1786.48% | -3391.36% |
| Gross Margin | 72.38% | - | - | - | - | - | - | - | - | - |
| Net Margin | -6719.64% | - | - | - | - | - | - | - | - | - |
| Debt / Equity | - | 6.56x | 0.02x | 0.13x | 0.01x | 0.00x | 0.03x | 0.03x | 0.04x | - |
| Interest Coverage | -7.83x | -50.50x | -28.07x | -107.36x | -53.84x | -33518.07x | - | - | - | - |
| FCF Conversion | 0.13x | 0.89x | 0.98x | 0.82x | 0.17x | 0.76x | 0.35x | 0.73x | 0.95x | 0.84x |
| Revenue Growth | -95.59% | -100% | - | - | - | - | - | - | - | - |
PCSA Frequently Asked Questions
Processa Pharmaceuticals, Inc. (PCSA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Processa Pharmaceuticals, Inc. (PCSA) grew revenue by 0.0% over the past year. Growth has been modest.
Processa Pharmaceuticals, Inc. (PCSA) reported a net loss of $13.6M for fiscal year 2025.
Dividend & Returns
Processa Pharmaceuticals, Inc. (PCSA) has a return on equity (ROE) of -373.0%. Negative ROE indicates the company is unprofitable.
Processa Pharmaceuticals, Inc. (PCSA) had negative free cash flow of $14.1M in fiscal year 2025, likely due to heavy capital investments.
Explore More PCSA
Processa Pharmaceuticals, Inc. (PCSA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates